HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-174775 | Technology
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Healthcare-associated Infectious Disease Diagnostics Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET
7.1 GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Abbott
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Accelerate Diagnostics
16.3 BD
16.4 bioMrieux
16.5 Bio-Rad
16.6 DiaSorin Molecular
16.7 F. Hoffmann-La Roche
16.8 Luminex
16.9 Meridian Bioscience
16.10 OpGen
16.11 QIAGEN
16.12 Quidel
16.13 Thermo Fisher Scientific
16.14 Trinity Biotech
16.15 Danaher
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Segment by TypeUrinary Tract Infections
Surgical Site Infections
Hospital-acquired Pneumonia
BloodStream Infections
Gastrointestinal Infections
Segment by Application
Hospitals
Clinics
ASCs
Companies
Abbott
Accelerate Diagnostics
BD
bioMrieux
Bio-Rad
DiaSorin Molecular
F. Hoffmann-La Roche
Luminex
Meridian Bioscience
OpGen
QIAGEN
Quidel
Thermo Fisher Scientific
Trinity Biotech
Danaher
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.